Insulin therapy for type 2 diabetes

Current Diabetes Reports

Volumn 3, Issue 5, 2003, Pages 378-385

  Sasali, Afshin ^b   Leahy, Jack L ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AMYLIN; GLARGINE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN RECEPTOR; INSULIN SENSITIZING AGENT; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LENTE; LONG ACTING DRUG; METFORMIN; ORAL ANTIDIABETIC AGENT; PROTAMINE; ROSIGLITAZONE; SHORT ACTING DRUG; SULFONYLUREA; TROGLITAZONE; UNCLASSIFIED DRUG; ZINC; ANTIDIABETIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET THERAPY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG USE; EXPERIENCE; FEAR; GLUCOSE BLOOD LEVEL; HEALTH PRACTITIONER; HUMAN; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PRESCRIPTION; RETINOPATHY; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TREATMENT FAILURE; WEIGHT GAIN; ARTERIOSCLEROSIS; CHEMICALLY INDUCED DISORDER; DIABETIC RETINOPATHY;

ARTERIOSCLEROSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; WEIGHT GAIN;

EID: 0242303617     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0081-2     Document Type: Review

References (54)

1. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
2. Economic costs of diabetes in the U.S. in 2002. American Diabetes Association [no authors listed]. Diabetes Care 2003, 26:917-932.
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854-865.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837-853.
5. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
6. Clinical practice recommendations 2003. American Diabetes Association [no authors listed]. Diabetes Care 2003, 26(suppl 1):S1-S156.
7. Saaddine JB, Engelau MM, Beckles GL, et al.: A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002, 136:565-574.
8. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287:360-372.
9. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002, 347:1342-1349.
10. Riddle MC: Timely addition of insulin to oral therapy for type 2 diabetes. Diabetes Care 2002, 25:395-396.
11. DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. Scientific review. JAMA 2003, 289:2254-2264.
12. DeWitt DE, Dugdale DC: Using new insulin strategies in the Outpatient treatment of diabetes. Clinical applications. JAMA 2003, 289:2265-2269.
13. Chan JL, Abrahamson MJ: Pharmacologic management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc 2003, 78:459-467.
14. Gerich JE: Novel insulins: expanding options in diabetes management. Am J Med 2002, 113:308-316.
15. Cohen FJ, Neslusan CA, Conklin JE, Song X: Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. Diabetes Care 2003, 26:1847-1851.
16. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002, 26(suppl 3):S18-S24.
17. Weyer C, Bogardus C, Mott DM, et al.: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104:787-794.
18. Butler AE, Janson J, Bonner-Weir S, et al.: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
19. Overview of 6 years therapy of type 2 diabetes: a progressive disease (UKPDS 16). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Diabetes 1995, 44:1249-1258.
20. Turner RC, Cull CA, Frighi V, et al.: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012.
21. Garvey WT, Olefsky JM, Griffin J, et al.: The effect of insulin treatment on insulin secretion and action in type 2 diabetes mellitus. Diabetes 1985, 34:222-234.
22. Kosaka K, Kuzuya T, Akanuma Y, et al.: Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980, 18:23-28.
23. Ilkova H, Glaser B, Tunckale A, et al.: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997, 20:1353-1356
24. Yale JF, Valiquett TR, Ghazzi MN, et al.: The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:737-745.
25. Kiayias JA, Vlachou ED, Theodosopoulou E, et al.: Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care 2002, 25:1251-1252.
26. Yki-Järvinen H, Ryysy L, Nikkila K, et al.: Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999, 130:389-396.
27. Rosenstock J, Riddle M, Dailey G, et al.: Treatment to target study: Feasibility of achieving control with the addition of basal bedtime insulin glargine or NPH insulin in insulin-naive patients with type 2 diabetes on oral agents [abstract]. Diabetes 2001, 50(suppl 2):A129.
28. Abraira C, Colwell JA, Nuttall FQ, et al.: Veterans affairs cooperative study on glycemic control and complications in type 2 diabetes (VA CSDM). Diabetes Care 1995, 18:1113-1123.
29. Avilés-Santa L, Sinding J, Raskin P: Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. Ann Intern Med 1999, 131:182-188.
30. Strowig SM, Avilés-Santa L, Raskin P: Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002, 25:1691-1698.
31. Wulffelé MG, Kooy A, Lehert P, et al.: Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002, 25:2133-2140.
32. Cryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes. Diabetes Care 2003, 26:1902-1912.
33. Harsch IA, Stocker S, Radespiel-Tröger M, et al.: Traffic hypoglycaemias and accidents in patients with diabetes mellitus treated with different antidiabetic regimens. J Intern Med 2002, 252:352-360.
34. Yki-Järvinen H, Dressler A, Ziemen M: Less nocturnal hypoglycemia and better post-dinner control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000, 23:1130-1136.
35. Rosenstock J, Schwartz SL, Clark CM, et al.: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine and NPH insulin. Diabetes Care 2001, 24:631-636.
36. Fritsche A, Schweitzer MA, Häring H-U: Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med 2003, 138:952-959.
37. White JR Jr, Campbell RK, Hirsch IB: Novel insulins and strict glycemic control. Analogues approximate normal insulin secretory response. Postgrad Med 2003, 113:30-36.
38. Després J-P, Lamarche B, Mauriége P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
39. Malmberg K: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997, 314:1512-1515.
40. Malmberg K, Norhammar A, Wedel H, Rydén L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999, 99:2626-2632.
41. Dandona P, Aijada A, Bandyopadhay A: The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. Diabetes Care 2003, 26:516-519.
42. Henricsson M, Berntorp K, Fernlund P, Sundkvist G: Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes Care 2002, 25:381-385.
43. Riddle MC, Hart JS, Bouma DJ, et al.: Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type 2 diabetes subjects. Diabetes Care 1989, 12:623-629.
44. Riddle MC, Schneider J: Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998, 21:1052-1057.
45. Riddle MC, Rosenstock J: Treatment to target study: insulin glargine vs NPH insulin added to oral therapy of type 2 diabetes. Successful control with less nocturnal hypoglycemia [abstract]. Diabetes 2002, 51(suppl 2):A113.
46. Yki-Järvinen: Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001, 24:758-767.
47. Wright A, Felix Burden AC, Paisey RB, et al.: Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25:330-336.
48. Hollander PA, Levy P, Fineman MS, et al.: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 2003, 26:784-790.
49. Cefalu WT: Evaluation of alternative strategies for optimizing glycemia: progress to date. Am J Med 2002, 113:23S-35S.
50. Skyler JS, Cefalu WT, Kourides IA, et al.: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet 2001, 3357:331-335.
51. Cefalu WT, Skyler JS, Kourides IA, et al.: Inhaled human insulin treatment in patients with type 2 diabetes. Ann Intern Med 2001, 134:203-207.
52. Zhang B, Salituro G, Szalkowski D, et al.: Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999, 289:2122-2125.
53. Air EL, Strowski MZ, Benoit SC, et al.: Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. Nat Med 2002, 8:179-183.
54. Kipnes M, Dandona P, Tripathy D, et al.: Control of postprandial glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 2003, 26:421-426.